Explore the highlights from FRPT 2024, featuring groundbreaking abstracts on Medscint's scintillation dosimetry solutions for FLASH and UHDR radiotherapy by Verdi Vanreusel, Riccardo dal Bello, and Yannick Poirrier.

🎯Spotlight on FRPT 2024
Scintillators Pushing Boundaries in FLASH Radiotherapy

In December, the Flash Radiotherapy and Particle Therapy 2024 Conference brought together in Rome – Italy some of the brightest minds in Ultra-High Dose Rate radiotherapy (UHDR or FLASH-RT), and we were thrilled to see Medscint’s scintillation dosimetry solutions showcased in several groundbreaking abstracts.

Here are three innovative abstracts selected for talk presentations that demonstrate the cutting-edge applications of our technology to push the boundaries of cancer care treatments with UHDR radiotherapy modalities:

🇨🇭 – Technical Preparation for a Phase 1 Clinical Study of eFLASH Radiotherapy for Palliative Treatment of Superficial Skin Lesions of Malignant Melanoma

This study outlines the preparation for a clinical trial assessing the feasibility and safety of electron FLASH radiotherapy for melanoma skin lesions, leveraging the precision of real-time plastic scintillators to enhance patient safety and treatment accuracy.

🇺🇸 – The Impact of Spatial and Temporal Dose Distributions on Achieving the FLASH Effect for Scanning Proton Beams

Leveraging the high temporal resolution of plastic scintillators, this study investigates how spatial and temporal dose distributions in scanning proton beams affect achieving the FLASH effect.

🇧🇪 – In-Vivo Dosimetry for UHDR Electron Beam FLASH Radiotherapy Using a Plastic and an Inorganic Point Scintillator System

This study highlights the precision and adaptability of the HYPERSCINT RP-200 scintillation dosimetry solution for ultra-high dose rate electron beam applications, paving the way for improved in-vivo measurement techniques.

Medscint Expertise for Accurate FLASH Radiotherapy Dosimetry

We are proud to see our scintillation dosimetry solutions driving innovation and supporting the development of new standards such as FLASH radiotherapy. A big thank you to our collaborators for their incredible work and for choosing Medscint as a partner in advancing the future of FLASH and UHDR radiotherapy.